kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Rolipram, 5 mg  

Rolipram, 5 mg


selective inhibitor of cAMP-specific phophodiesterase, PDE IV

More details


Availability: within 3 days

95,00 €

Rolipram is a selective inhibitor of cAMP-specific phophodiesterase, PDE IV, and thus prevents the degradation of the second messenger cAMP by this enzyme. Molecular weight 275.4 g/mol. Solubility: Soluble in DMSO and Ethanol. Appearance: White solid. Purity: >98%. Formula C16H21N03. CAS number: 61413-54-5

synonyms: ZK-62711, ZK 62711

Product specific literature references:

Kato H, Araki T, Itoyama Y, Kogure K (1995) "Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil" Eur. J. Pharmacol. 272(1):107-10

MacKenzie SJ, Houslay MD (2000) "Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells" Biochem. J. 347(Pt 2):571-8

Vitolo OV, Sant\'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M (2002) "Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling" Proc Natl Acad Sci USA 99(20):13217-21

Itoh T, Tokumura M, Abe K (2004) "Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats" Eur. J. Pharmacol. 498(1-3):135-42

Navakkode S, Sajikumar S, Frey JU (2004) "The type IV-specific phosphodiesterase inhibitor rolipram and its effect on hippocampal long-term potentiation and synaptic tagging" J. Neurosci. 24(35):7740-4

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.